⌘K

21:39:26·71d

SECFilingvia Quantisnow

Amendment: SEC Form SCHEDULE 13G/A filed by Verrica Pharmaceuticals Inc.

ByQuantisnow·Wall Street's wire, on your screen.

VRCA· Verrica Pharmaceuticals Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

VRCA
Verrica Pharmaceuticals Inc.
Health Care

Recent analyst ratings

Nov 6UpdateH.C. Wainwright-
Nov 5UpdateRBC Capital Mkts-
Jul 25UpdateNeedham$10.00
Mar 22UpdateJefferies$10.00
Feb 13UpdateRBC Capital Mkts$11.00
May 25UpdateRBC Capital Mkts$4.00

Related

SEC9d
SEC Form DEFA14A filed by Verrica Pharmaceuticals Inc.
SEC9d
SEC Form DEF 14A filed by Verrica Pharmaceuticals Inc.
PR20d
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
PR24d
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
SEC50d
SEC Form 10-K filed by Verrica Pharmaceuticals Inc.
SEC50d
Verrica Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
PR50d
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
PR55d
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026